Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06906939 · ClinicalTrials.gov registry record · Early Phase 1

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

A Early Phase 1 study of Depression and Knee Osteoarthritis, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06906939 is a Early Phase 1 study of Depression and Knee Osteoarthritis that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06906939, a Early Phase 1 study of Depression and Knee Osteoarthritis, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Osteoarthritis (OA) is a major public health problem, and involvement of the knee is especially disabling. Symptomatic knee OA has an incidence rate between 40 to 1,020 per 100,000 person years1 and is among the most common causes of disability worldwide. Knee arthritis pain and disability are highly comorbid wiht depression (30-50%). Currently available treatments offer only limited relief. The Pilot project aims to establish feasibility of the rTMS neuromodulation of response to Tai Chi and improvement in pain and comorbid depression in patients with knee OA. There are several ways in which the pilot project will improve scientific knowledge, and clinical practice: 1) The sequential stimulation of two targets (M1 and l-DLPFC) has not been systematically examined for the treatment of comorbid MDD and knee OA. We hypothesize that using a multi-target rTMS strategy combining M1 and l-DLPFC- active targets will be well tolerated and more effective to treat comorbid symptoms than single site rTMS to M1+l-DLPFCsham. This hypothesis will be tested in Aim 1 of this proposal by comparing two experimental conditions: A) M1active and l-DLPFCactive; and B) M1active and l-DLPFCsham. 2) Identifying the relationship between improvement in pain and depression to improvement in pro-inflammatory cytokines would be novel. Adding an rTMS as a neuromodulation technique with novel stimulation sites to assist in the reduction of symptoms of pain and depression is another scalable to clinical use opportunity that will provide pilot data for future clinical trials. We will perform a pilot feasibility trial of rTMS for those presenting with knee osteoarthritis related pain and moderate to severe depression in 30 volunteers who are undergoing Tai Chi intervention. Tolerability and safety of rTMS added to Tai Chi will be assessed along with changes in symptoms of pain and depression, in preparation to future R-01 applications.

Interventions

  • DEVICE repetetive transcranial magnetic stimulation

Study Locations (1)

California

  • UCLA Semel Institute - Neuropsychiatric Institute (NPI) - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-04-01
Est. Completion 2029-06-30
Phase Early Phase 1

What the Registry Record Tells You About NCT06906939

The ClinicalTrials.gov registry entry for NCT06906939 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which repetetive transcranial magnetic stimulation is the first listed.

NCT06906939 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06906939 about?

NCT06906939 is a clinical study titled "A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression". Osteoarthritis (OA) is a major public health problem, and involvement of the knee is especially disabling. Symptomatic knee OA has an incidence rate between 40 to 1,020 per 100,000 person years1 and is among the most common causes of disability worldwide. Knee arthritis pain and disability are highl...

What is the current status of trial NCT06906939?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2026-04-01. Estimated completion is 2029-06-30.

What conditions does trial NCT06906939 study?

This clinical trial studies the following conditions: Depression, Knee Osteoarthritis.

What interventions are being tested in trial NCT06906939?

The interventions under investigation include: repetetive transcranial magnetic stimulation (DEVICE).

Who is sponsoring clinical trial NCT06906939?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06906939 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.